Jan 26 2009 11:42

P. 09

TURCHETTA et al Appl. No. 10/580,173 | January 26, 2009 RECEIVED CENTRAL FAX CENTER JAN 2 6 2009

REMARKS/ARGUMENTS

In response to the Restriction requirement, Applicants hereby elect Group I, namely, claims 34-38 and 47-56, drawn to a form A.

Review of the specification has revealed the presence of certain typographical errors. These have been corrected in the present response. The following comments are offered

- 1. The chemical name of moxifloxacin contains extraneous brackets and the term "dicyclo" appears instead of "bicyclo". The corrected version is 1-cyclopropyl-7-(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride. This appears in the title, the Abstract, and in paragraphs [0001] and [0002]. Each has been corrected accordingly.
- 2. A new Abstract is presented reflecting the above changes and the removal of "p1" before point c).
- 3. Paragraph [0012], has been amended to start a new line beginning from the words "a novel hydrate..."
- 4. The period appearing after "C" (indicating degrees centigrade) in paragraphs [0005], [0040], [0043]-[0047], [0050] and [0051] has been removed.

No new matter is entered. Further action is awaited.

Best Available Copy

-- NIXON & VANDERHYE PC3 Fax: 703-816-4100

Jan 26 2009 11:42

P. 10

TURCHETTA et al Appl. No. 10/580,173 January 26, 2009

Respectfully submitted,

NIXON & VANDERHYE P.C.

Ву:

eonard C Michard Reg. No. 29,009

LCM:Iff 901 North Glebe Road, 11th Floor Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100